DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Triamcinolone (Triamcinolone Acetonide Topical) - Summary

 
 



TRIAMCINOLONE SUMMARY

Triamcinolone acetonide is a topical corticosteroid. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents.

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.


See all Triamcinolone indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Triamcinolone (Triamcinolone Acetonide Topical)

The effect of an absorbable gelatin dressing impregnated with triamcinolone within the olfactory cleft on polypoid rhinosinusitis smell disorders. [2014]
function in patients who underwent sinus surgery... CONCLUSION: We suggest that application of triamcinolone at the olfactory cleft

Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids. [2012]
for treatment of keloids... CONCLUSION: 5-FU tattooing was more effective than intralesional TAC for the

Intravitreal triamcinolone versus laser photocoagulation as a primary treatment for diabetic macular oedema - a comparative pilot study. [2011.11.23]
ABSTRACT: BACKGROUND: Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduces the risk of visual loss. However recurrences are common and despite laser treatment, patients with diabetic macular oedema experienced progressive loss of vision. Stabilization of the blood retinal barrier introduces a rationale for intravitreal triamcinolone treatment in diabetic macular oedema. This study is intended to compare the best corrected visual acuity (BCVA) and the macular oedema index (MEI) at 3 month of primary treatment for diabetic macular oedema between intravitreal triamcinolone acetonide (IVTA) and laser photocoagulation... CONCLUSIONS: IVTA demonstrates good outcome comparable to laser photocoagulation as a primary treatment for diabetic macular oedema at three months post treatment. TRIAL REGISTRATION: ISRCTN05040192 (http://www.controlled-trial.com).

Adding Triamcinolone to Endoscopic Ultrasound-Guided Celiac Plexus Blockade Does Not Reduce Pain in Patients With Chronic Pancreatitis. [2011.09.22]
BACKGROUND & AIMS: The efficacy of endoscopic ultrasound-guided celiac plexus blockade (EUS-CPB) for painful chronic pancreatitis (CP) is uncertain. Triamcinolone is often mixed with bupivacaine to lengthen the analgesic effect. We investigated whether addition of triamcinolone increases and lengthens pain relief compared with EUS-CPB with only bupivacaine... CONCLUSIONS: Triamcinolone does not increase pain relief or lengthen the effects of EUS-CPB. Copyright (c) 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Effects of intracameral triamcinolone and gentamicin injections following cataract surgery. [2011.07]
CONCLUSION: Intracameral injections of triamcinolone acetonide and gentamicin appear to be a promising treatment option for the control of post-operative inflammation following cataract surgery.

more studies >>

Clinical Trials Related to Triamcinolone (Triamcinolone Acetonide Topical)

Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis [Recruiting]
It is currently unknown whether or not the improvement in pain and function related to a "steroid shot" for shoulder pain due to subacromial bursitis is important. This study seeks to determine whether 20 mg or 40 mg of either triamcinolone or methylprednisolone significantly affect improvement in shoulder pain 6 weeks after injection.

A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema [Completed]
The study involves the enrollment of patients over 18 years of age with diabetic macular edema involving the center of the macula who have not already been given maximal laser treatment. Patients with one study eye will be randomly assigned (stratified by prior laser) with equal probability to one of five treatment groups: 1. Focal laser photocoagulation (modified ETDRS technique) 2. Posterior peribulbar injection of 40 mg triamcinolone (Kenalog) 3. Anterior peribulbar injection of 20 mg triamcinolone 4. Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser 5. Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser For patients with two study eyes (both eyes eligible at the time of randomization), the right eye (stratified by prior laser) will be randomly assigned with equal probabilities to one of the five treatment groups listed above. If the right eye was assigned to laser only, then the left eye will be assigned to one of the four triamcinolone groups above with equal probability (stratified by prior laser). If the right eye was assigned to receive triamcinolone, then the left eye will receive laser only. Triamcinolone acetonide will be the corticosteroid utilized in this study. The triamcinolone acetonide preparation to be used is Kenalog. Kenalog is manufactured by Bristol Myers Squibb and is approved by the Food and Drug Administration for intramuscular use for a variety of indications. Peribulbar injections of Kenalog have been used for a wide variety of ocular conditions, particularly uveitis and post-cataract extraction cystoid macular edema, for many years. Two different triamcinolone regimens will be assessed in the study: 40 mg injected posteriorly and 20 mg injected anteriorly. There is no indication of which treatment regimen will be better. Although the injection behind the eye is more common than the injection near the front of the eye, the injection near the front of the eye has less risk of injuring the eye. However, it is possible that the injection near the front of the eye may increase eye pressure more frequently. Little is known about which of the two injections decreases macular edema and improves vision more often. Patients enrolled into the study will be followed for three years and will have study visits 1 month, 2 months, 4 months, 8 months and annually after receiving their assigned study treatment. For the first 8 months of the study, patients should only be retreated with their randomized treatment. However, if the patient's visual acuity has decreased by 15 letters or more, then any treatment may be given at the investigator's discretion. After completion of the 8-month visit, treatment is at investigator discretion. The primary objective of this study is to obtain estimates of efficacy and safety outcomes for each of the treatment groups. These estimates will provide a basis for the sample size estimation and hypothesis generation in a phase III trial.

Intralesional Steroids in the Treatment of Alopecia Areata [Recruiting]
Alopecia areata is a common form of hair loss which reportedly occurs in up to 1. 7% of the population at some time in their life. Alopecia areata is apparently triggered when the individual's own immune system attacks hair follicles on the scalp or body resulting in hair loss ranging from single patches on the scalp (patch type alopecia areata) to loss of every hair on the scalp and body (alopecia universalis). Currently, there are limited treatment options for alopecia areata and unfortunately, the treatments utilized have never been rigorously tested in a placebo controlled trial. Triamcinolone (Kenalog) is a steroid solution that has been used as treatment for alopecia areata for over 50 years. It is administered via injection into the scalp and appears to have some efficacy for patients with mild to moderate alopecia areata. We currently do not have objective data on the frequency of occurrence of successful regrowth, the duration of response or the incidence of side effects. In addition, there is disagreement between clinicians regarding the dose of intralesional triamcinolone (IL TAC) that is considered most effective. This study aims to determine the frequency of response to treatment with 3 concentrations of IL TAC, 2. 5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of side effects compared to treatment with placebo (sterile saline solution). After the 1st 6 months non or partial responders may be treated for 6 months with open label triamcinolone at the dose deemed appropriate by the investigator. We will also perform skin biopsies of the scalp and draw blood at selected time points in order to examine the immunohistochemical/pathological response in scalp hair follicles and the systemic circulation to treatment with IL TAC for alopecia areata.

Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema [Recruiting]

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis [Active, not recruiting]
This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.

more trials >>

Reports of Suspected Triamcinolone (Triamcinolone Acetonide Topical) Side Effects

Nausea (6)Cough (5)Drug Ineffective (4)Pain (4)Fatigue (4)Vomiting (4)Anxiety (4)Insomnia (4)Feeling Abnormal (4)Glaucoma (3)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 2 ratings/reviews, Triamcinolone has an overall score of 9.50. The effectiveness score is 9 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Triamcinolone review by 33 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   skin exema
Dosage & duration:   0.1% application (dosage frequency: 3 times daily) for the period of 1 month
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   My therapist prescribe this cream, as I develpe dark sport on my skin on the back from exema. The sport were itchy so I couldn't sleep well and they turned dark due to post-inflammatory hyper pigmentation. I am still using the cream but it effectively eliminated any itching and dark sport reduce in size and became lighter. In fact, my therapist later prescribed a more potent cream, betamethasone dipropionate 0.05%, but I felt that the first one was more effective in my case.
Side effects:   none
Comments:   I used 0.1% cream three times daily on clean skin for one month

 

Triamcinolone review by care giver of 7 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Eczema
Dosage & duration:   Apply twice daily (dosage frequency: twice daily) for the period of 2 months
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   If used regularly, this treatment eliminates the white and rough spots my daughter gets all over her arms and hands (and in some cases, her legs).
Side effects:   As far as I can tell, no side effects noted.
Comments:   When starting the treatment for the first time, I apply a light amount both morning and evenings. After a few weeks, I apply only once in the evening.

See all Triamcinolone reviews / ratings >>

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015